Victoria de Poo-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Victoria de Poo-Rodríguez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alberto Anel
Immunity & Cancer Group, IIS Aragón, University of Zaragoza
1 shared publication- Alfonso Serrano Del Valle
Apoptosis, Immunity & Cancer Group, IIS Aragón University of Zaragoza Spain
1 shared publication Beatriz Martínez-Lázaro
Hospital Clínico Universitario Lozano Blesa
1 shared publication- Gemma Azaceta
Hematology Department, Lozano Blesa Clinical Hospital, 50009 Zaragoza, Spain
1 shared publication Isabel Izquierdo
Immunity & Cancer Group, IIS Aragón, University of Zaragoza
1 shared publication- Isabel Marzo
Apoptosis, Immunity and Cancer Group, Department of Biochemistry and Molecular and Cell Biology, Aragon Health Research Institute (IIS-Aragon), University of Zaragoza, 50009 Zaragoza, Spain
1 shared publication
Latest Publications
- Open Access
- 1 November 2022
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2141973
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis
Immunogenic cell death (ICD) has been proposed to be a crucial process for antitumor immunosurveillance. ICD is characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP), including calreticulin (CRT). A positive correlation between CRT exposure or total expression and improved anticancer immunosurveillance has been found in certain cancers, usually accompanied by favorable patient prognosis. In the present study, we sought to evaluate CRT levels in the plasma membrane of CD38+ bone marrow mononuclear cells (BMMCs) isolated from 71 patients with varying degrees of multiple myeloma (MM) disease and examine the possible relationship between basal CRT exposure and the bone marrow immune microenvironment, as well as its connection with different clinical markers. Data show that increased levels of cell surface-CRT were associated with more aggressive clinical features and with worse clinical prognosis in MM. High CRT expression in MM cells was associated with increased infiltration of NK cells, CD8+ T lymphocytes and dendritic cells (DC), indicative of an active anti-tumoral immune response, but also with a significantly higher presence of immunosuppressive Treg cells and increased expression of PD-L1 in myeloma cells.
- 1 November 2022
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2141973
Open AccessEcto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis
Immunogenic cell death (ICD) has been proposed to be a crucial process for antitumor immunosurveillance. ICD is characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP), including calreticulin (CRT). A positive correlation between CRT exposure or total expression and improved anticancer immunosurveillance has been found in certain cancers, usually accompanied by favorable patient prognosis. In the present study, we sought to evaluate CRT levels in the plasma membrane of CD38+ bone marrow mononuclear cells (BMMCs) isolated from 71 patients with varying degrees of multiple myeloma (MM) disease and examine the possible relationship between basal CRT exposure and the bone marrow immune microenvironment, as well as its connection with different clinical markers. Data show that increased levels of cell surface-CRT were associated with more aggressive clinical features and with worse clinical prognosis in MM. High CRT expression in MM cells was associated with increased infiltration of NK cells, CD8+ T lymphocytes and dendritic cells (DC), indicative of an active anti-tumoral immune response, but also with a significantly higher presence of immunosuppressive Treg cells and increased expression of PD-L1 in myeloma cells.